NEW YORK (GenomeWeb News) – Accelerate Diagnostics today said that its revenues in the second quarter dropped three-fold year over year.

Revenues for the three months ended June 30 were $7,373, down from $22,721 a year ago, Accelerate said in its Form 10-Q filed with the US Securities and Exchange Commission. All revenues for the recently completed quarter and the year-ago period derived from royalty payments for its OptiChem products.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers test gene therapy targeting a different cancer protein in a new trial, the New York Times reports.

Pennsylvania State University researchers found that salivary microRNAs could predict which kids would have longer concussion symptoms, according to NPR.

The Associated Press reports Alex Azar, the new Department of Health and Human Services secretary nominee, made millions of dollars as a pharmaceutical executive.

In PNAS this week: immune profiling of breast cancer, transposable element patterns in rice, and more.